Market Overview:
The global nanostructured drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of cancer and tumors, autoimmune disorders, and other chronic diseases. In addition, the growing demand for targeted therapies is also contributing to the growth of this market. The global nanostructured drug market can be segmented on the basis of type into liposomes, polymeric micelles, solid lipid nanoparticles (SLN), microemulsion and nanoemulsion, and nanosuspension. On the basis of application, this market can be divided into cancer and tumors, autoimmune disorders such as rheumatoid arthritis (RA), Crohn’s disease (CD), psoriasis vulgaris (PV), multiple sclerosis (MS) etc., central nervous system disorders such as Alzheimer’s disease (AD) and Parkinson’s disease(PD), ophthalmic diseases such as age-related macular degeneration(AMD) etc., cardiovascular diseases such as atherosclerosis etc., respiratory diseases such as asthma etc., gastrointestinal diseases such as ulcerative colitis etc., genitourinary tract infections including urinary tract infection UTI ), skin infections & topical applications ,and others which include endocrine disorders & diabetes mellitus).
Product Definition:
A nanostructured drug is a drug that has been designed or engineered to have a specific size and shape. This size and shape can help to improve the effectiveness of the drug, as well as its safety. Nanostructured drugs are becoming increasingly important in modern medicine, as they can be used to treat a wide variety of diseases.
Liposomes:
Liposomes are small vesicular structures composed of phospholipids and water. They are naturally occurring organelles that play a major role in the delivery of drugs to specific target cells. Liposomes are commonly used as drug carriers because they can efficiently deliver drugs to target cells with minimum side effects.
Polymeric Micelles:
Polymeric micelles are colloidal systems formed by the aggregation of multiple polymers. They have a wide range of applications in nanostructured drug delivery including, drug-polymer interaction, sustained release and controlled release. Polymeric micelles can be used as model systems to study the influence of various parameters on their physical properties and interactions such as surface area, hydrophobicity, ionic strength and molecular weight among others.
Application Insights:
The cancer and tumor segment dominated the global market in terms of revenue share in 2017. This is attributed to the high prevalence of cancer across the globe. According to WHO, it has been estimated that around 1 in 6 people dies from cancer. In addition, an estimated 9 out of 10 deaths due to cancer occur globally. Thus, a significant number of patients suffering from various types of cancers seek treatment worldwide which contributes towards growth within this segment.
Solid lipid nanoparticle (SLN) based drugs are known for their ability to penetrate cell membranes and act as Trojan horses inside cells where they can deliver drugs with efficiency compared with other nanotechnology-based drug delivery systems available in the market at present time owing to its ability to overcome barriers faced by other nanotechnology-based drug delivery systems such as bioadhesion & internalization problems associated with SLN formulations used for targeted/smart Delivery (TDD).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of companies, which are engaged in nanotechnology-based drug discovery and development. Moreover, increasing R&D investments by various government organizations and academic institutes is expected to fuel growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising healthcare expenditure by governments as well as private sectors across countries such as China, India, South Korea, Singapore among others are expected boost regional market growth over next eight years.
Growth Factors:
- Increasing demand for nanotechnology-based drugs and therapies for the treatment of various diseases
- Rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders that can be treated with nanostructured drugs
- Growing investments by pharmaceutical companies in R&D for the development of novel nanostructured drug delivery systems
- Proliferation of contract research organizations (CROs) that offer specialized services for the development and commercialization of nanostructured drugs
- Emergence of new applications areas such as regenerative medicine, which is expected to fuel demand for nanostructured drug products
Scope Of The Report
Report Attributes
Report Details
Report Title
Nanostructured Drug Market Research Report
By Type
Liposomes, Polymeric Micelles, Solid lipid Nanoparticles, Microemulsion and Nanoemulsion, Nanosuspension
By Application
Cancer and Tumors, Autoimmune Disorders
By Companies
Merck, Pfizer, Novartis, Abbott, GlaxoSmithKline, Roche, Sanofi, Eli Lilly, Astrazeneca, Johnson & Johnson, Celgene, Novavax, Stryker, Gilead Sciences, OSI Pharmaceuticals, Kadmon Pharmaceuticals, Samyang Biopharm, Mitsubishi Pharma , Kaken Pharmaceutical, Selecta Biosciences, Par Pharmaceutical, Cerulean Pharma, Navidea Biopharmaceuticals, Lummy
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Nanostructured Drug Market Report Segments:
The global Nanostructured Drug market is segmented on the basis of:
Types
Liposomes, Polymeric Micelles, Solid lipid Nanoparticles, Microemulsion and Nanoemulsion, Nanosuspension
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cancer and Tumors, Autoimmune Disorders
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Pfizer
- Novartis
- Abbott
- GlaxoSmithKline
- Roche
- Sanofi
- Eli Lilly
- Astrazeneca
- Johnson & Johnson
- Celgene
- Novavax
- Stryker
- Gilead Sciences
- OSI Pharmaceuticals
- Kadmon Pharmaceuticals
- Samyang Biopharm
- Mitsubishi PharmaÂ
- Kaken Pharmaceutical
- Selecta Biosciences
- Par Pharmaceutical
- Cerulean Pharma
- Navidea Biopharmaceuticals
- Lummy
Highlights of The Nanostructured Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Liposomes
- Polymeric Micelles
- Solid lipid Nanoparticles
- Microemulsion and Nanoemulsion
- Nanosuspension
- By Application:
- Cancer and Tumors
- Autoimmune Disorders
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Nanostructured Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Nanostructured drugs are drug molecules that have been specifically designed with nanometer-scale features. These features can improve the drug's ability to cross the blood-brain barrier, interact with specific receptors in the brain, or penetrate cancer cells.
Some of the key players operating in the nanostructured drug market are Merck, Pfizer, Novartis, Abbott, GlaxoSmithKline, Roche, Sanofi, Eli Lilly, Astrazeneca, Johnson & Johnson, Celgene, Novavax, Stryker, Gilead Sciences, OSI Pharmaceuticals, Kadmon Pharmaceuticals, Samyang Biopharm, Mitsubishi Pharma‚Â , Kaken Pharmaceutical, Selecta Biosciences, Par Pharmaceutical, Cerulean Pharma, Navidea Biopharmaceuticals, Lummy.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Nanostructured Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Nanostructured Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Nanostructured Drug Market - Supply Chain
4.5. Global Nanostructured Drug Market Forecast
4.5.1. Nanostructured Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Nanostructured Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Nanostructured Drug Market Absolute $ Opportunity
5. Global Nanostructured Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Nanostructured Drug Market Size and Volume Forecast by Type
5.3.1. Liposomes
5.3.2. Polymeric Micelles
5.3.3. Solid lipid Nanoparticles
5.3.4. Microemulsion and Nanoemulsion
5.3.5. Nanosuspension
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Nanostructured Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Nanostructured Drug Market Size and Volume Forecast by Application
6.3.1. Cancer and Tumors
6.3.2. Autoimmune Disorders
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Nanostructured Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Nanostructured Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Nanostructured Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Nanostructured Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Nanostructured Drug Demand Share Forecast, 2019-2029
9. North America Nanostructured Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Nanostructured Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Nanostructured Drug Market Size and Volume Forecast by Application
9.4.1. Cancer and Tumors
9.4.2. Autoimmune Disorders
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Nanostructured Drug Market Size and Volume Forecast by Type
9.7.1. Liposomes
9.7.2. Polymeric Micelles
9.7.3. Solid lipid Nanoparticles
9.7.4. Microemulsion and Nanoemulsion
9.7.5. Nanosuspension
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Nanostructured Drug Demand Share Forecast, 2019-2029
10. Latin America Nanostructured Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Nanostructured Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Nanostructured Drug Market Size and Volume Forecast by Application
10.4.1. Cancer and Tumors
10.4.2. Autoimmune Disorders
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Nanostructured Drug Market Size and Volume Forecast by Type
10.7.1. Liposomes
10.7.2. Polymeric Micelles
10.7.3. Solid lipid Nanoparticles
10.7.4. Microemulsion and Nanoemulsion
10.7.5. Nanosuspension
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Nanostructured Drug Demand Share Forecast, 2019-2029
11. Europe Nanostructured Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Nanostructured Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Nanostructured Drug Market Size and Volume Forecast by Application
11.4.1. Cancer and Tumors
11.4.2. Autoimmune Disorders
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Nanostructured Drug Market Size and Volume Forecast by Type
11.7.1. Liposomes
11.7.2. Polymeric Micelles
11.7.3. Solid lipid Nanoparticles
11.7.4. Microemulsion and Nanoemulsion
11.7.5. Nanosuspension
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Nanostructured Drug Demand Share, 2019-2029
12. Asia Pacific Nanostructured Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Nanostructured Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Nanostructured Drug Market Size and Volume Forecast by Application
12.4.1. Cancer and Tumors
12.4.2. Autoimmune Disorders
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Nanostructured Drug Market Size and Volume Forecast by Type
12.7.1. Liposomes
12.7.2. Polymeric Micelles
12.7.3. Solid lipid Nanoparticles
12.7.4. Microemulsion and Nanoemulsion
12.7.5. Nanosuspension
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Nanostructured Drug Demand Share, 2019-2029
13. Middle East & Africa Nanostructured Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Nanostructured Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Nanostructured Drug Market Size and Volume Forecast by Application
13.4.1. Cancer and Tumors
13.4.2. Autoimmune Disorders
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Nanostructured Drug Market Size and Volume Forecast by Type
13.7.1. Liposomes
13.7.2. Polymeric Micelles
13.7.3. Solid lipid Nanoparticles
13.7.4. Microemulsion and Nanoemulsion
13.7.5. Nanosuspension
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Nanostructured Drug Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Nanostructured Drug Market: Market Share Analysis
14.2. Nanostructured Drug Distributors and Customers
14.3. Nanostructured Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Merck
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Pfizer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Novartis
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Abbott
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. GlaxoSmithKline
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Roche
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Sanofi
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Eli Lilly
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Astrazeneca
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Johnson & Johnson
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Celgene
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Novavax
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Stryker
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Gilead Sciences
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. OSI Pharmaceuticals
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Kadmon Pharmaceuticals
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Samyang Biopharm
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Mitsubishi Pharma
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. Kaken Pharmaceutical
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. Selecta Biosciences
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
